Date Title Description PDF
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download
22 Jun 2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Download
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download

Pages

Date Title Description PDF
24 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 January 2021 and 21 January 2021 Download
17 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 10 January 2021 and 14 January 2021 Download
10 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 3 January 2021 and 7 January 2021 Download
03 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 27 December 2021 and 31 December 2021 Download
28 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 20 December 2021 and 24 December 2021 Download

Pages

Date Title Description PDF
04 Apr 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the first quarter of 2019 Download
19 Mar 2019 R&D: new licenses, patents and registered trademarks ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia Download
26 Feb 2019 Informe Anual de Remuneraciones de los Consejeros ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors  Download
26 Feb 2019 Informe Anual de Gobierno Corporativo ROVI releases the 2018 Annual Corporate Governance Report Download
26 Feb 2019 Otros sobre gobierno corporativo The Company informs about the agreements adopted by the Board of Directors Download

Pages